Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Bai, Peng ^a   Sun, Yongchang ^a   Jin, Jianmin ^a   Hou, Jia ^a   Li, Ran ^a   Zhang, Qing ^a   Wang, Yang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chronic obstructive pulmonary disease; Cytokine; Opg rank rankl; Osteoporosis; Pulmonary emphysema

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPNEA; EMPHYSEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMUR NECK; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMAGE ANALYSIS; INFLAMMATION; LUMBAR SPINE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; SMOKING; SYSTEMIC INFLAMMATION; THORAX RADIOGRAPHY; BLOOD; FEMALE; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; CYTOKINES; EMPHYSEMA; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPROTEGERIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 83455238443     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-157     Document Type: Article

References (36)

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006, 27:397-412. 10.1183/09031936.06.00025805, 16452599.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Gold executive summary. Am J Respir Crit Care Med 2007, 176:532-555. 10.1164/rccm.200703-456SO, 17507545.
3. Agusti AG, Soriano JB. COPD as a systemic disease. COPD 2008, 5:133-138. 10.1080/15412550801941349, 18415812.
4. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. 2003, Washington, DC. National Osteoporosis Foundation.
5. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:347-360. 10.1183/09031936.03.00405703, 12608452.
6. Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Mark S. Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 1999, 116:1616-1624. 10.1378/chest.116.6.1616, 10593785.
7. Katsura H, Kida K. A comparison of bone mineral density in elderly female patients with COPD and bronchial asthma. Chest 2002, 122:1949-1955. 10.1378/chest.122.6.1949, 12475832.
8. Kjensli A, Mowinckel P, Ryg MS, Falch JA. Low bone mineral density is related to severity of chronic obstructive pulmonary disease. Bone 2007, 40:493-497. 10.1016/j.bone.2006.09.005, 17049326.
9. Vrieze A, de Greef MH, Wy'kstra PJ, Wempe JB. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int 2007, 18:1197-1202. 10.1007/s00198-007-0355-7, 17347789.
10. Mineo TC, Ambrogi V, Mineo D, Fabbri A, Fabbrini E, Massoud R. Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest 2005, 127:1960-1966. 10.1378/chest.127.6.1960, 15947308.
11. Blake GM, Knapp KM, Fogelman I. Dual X-ray absorptiometry-clinical evaluation of a new cone-beam system. Calcif Tissue Int 2005, 76:113-120. 10.1007/s00223-004-0080-6, 15645160.
12. Madani A, Zanen J, de Maertelaer V, Gevenois PA. Pulmonary emphysema: objective quantification at multi-detector row CT; comparison with macroscopic and microscopic morphometry. Radiology 2006, 238:1036-1043. 10.1148/radiol.2382042196, 16424242.
13. Garcia-Rio F, Miravitlles M, Soriano JB, Muñoz L, Duran-Tauleria E, Sánchez G, Sobradillo V, Ancochea J, . EPI-SCAN Steering Committee Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respiratory Research 2010, 11:63. 2891677, 20500811, EPI-SCAN Steering Committee.
14. Barnes PJ, Celli BR. Systemic manifestation and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185. 10.1183/09031936.00128008, 19407051.
15. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:71-78. 10.1164/rccm.200505-704OC, 16179639.
16. Gregory R, Mundy MD. Osteoporosis and Inflammation. Nutrition Reviews 2007, 65:S147-S151. 10.1301/nr.2007.dec.S147-S151, 18240539.
17. McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep 2009, 7:134-139. 10.1007/s11914-009-0023-2, 19968917.
18. Kwan TS, Padrines M, Théoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004, 15:49-60. 10.1016/j.cytogfr.2003.10.005, 14746813.
19. Théoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 15:457-475. 10.1016/j.cytogfr.2004.06.004, 15561602.
20. Bon J, Fuhrman CR, Weissfeld JL, Duncan SR, Branch RA, Chang CH, Zhang Y, Leader JK, Gur D, Greenspan SL, Sciurba FC. Radiographic Emphysema Predicts Low Bone Mineral Density in a Tobacco-exposed Cohort. Am J Respir Crit Care Med 2011, 183:885-890. 10.1164/rccm.201004-0666OC, 20935108.
21. American Thoracic Society Surveillance for respiratory hazards in the occupational setting. Am Rev Respir Dis 1982, 126:952-956. American Thoracic Society.
22. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six minute walk test. Am J Respir Crit Care Med 2002, 116:111-117. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.
23. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Plata P. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012. 10.1056/NEJMoa021322, 14999112.
24. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34:648-654. 10.1183/09031936.00102509, 19720809.
25. Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 169:855-859. 10.1164/rccm.200307-926OC, 14711795.
26. Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, Nixon LS, Evans WD, Griffiths TL, Shale DJ. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:1286-1293. 10.1164/rccm.200406-754OC, 15374843.
27. Duckers JM, Evans BA, Fraser WD, Stone MD, Bolton CE, Shale DJ. Low bone mineral density in men with chronic obstructive pulmonary disease. Respiratory Research 2011, 12:101. 10.1186/1465-9921-12-101, 3161864, 21812978.
28. Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, Marumo S, Ogawa E, Hoshino Y, Niimi A, Chin K, Mishima M. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008, 134:1244-1249. 10.1378/chest.07-3054, 18641115.
29. Bon JM, Leader JK, Weissfeld JL, Coxson HO, Zheng B, Branch RA, Kondragunta V, Lee JS, Zhang Y, Choi AMK, Lokshin AE, Kaminski N, Gur D, Sciurba FC. The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS ONE 4(8):e6865.
30. Ragab AA, Nalepka JL, Bi Y, Greenfield EM. Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. Am J Physiol Cell Physiol 2002, 283:C679-687.
31. Horowitz MC, Xi Y, Wilson K, Kacena MA. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001, 12:9-18. 10.1016/S1359-6101(00)00030-7, 11312114.
32. Fouque-Aubert A, Chapurlat R. Influence of RANKL inhibition on immune system in the treatment of bone diseases. Joint Bone Spine 2008, 75:5-10. 10.1016/j.jbspin.2007.05.004, 17920324.
33. Simonet WS, Lacey DL, Dunstan CR, Kelley MC, Hang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, RenshawGegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319. 10.1016/S0092-8674(00)80209-3, 9108485.
34. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176. 10.1016/S0092-8674(00)81569-X, 9568710.
35. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055. 10.1210/en.142.12.5050, 11713196.
36. Eagan T, Ueland T, Wagner PD, Hardie JA, Mollnes TE, Dams JK, Aukrust P, Bakke PS. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J 2010, 35:540-548. 10.1183/09031936.00088209, 19643942.